---
title: "H.C. Wainwright Sticks to Their Buy Rating for Protagonist Therapeutics (PTGX)"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/285412538.md"
description: "H.C. Wainwright analyst Douglas Tsao has reaffirmed a Buy rating for Protagonist Therapeutics (PTGX) with a price target of $117.00. Tsao, who specializes in the Healthcare sector, has an average return of 21.2% and a 52.10% success rate on his stock recommendations. Additionally, Barclays analyst Etzer Darout also issued a Buy rating for the company, while Goldman Sachs maintained a Hold rating on the stock."
datetime: "2026-05-06T16:37:20.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/285412538.md)
  - [en](https://longbridge.com/en/news/285412538.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/285412538.md)
---

# H.C. Wainwright Sticks to Their Buy Rating for Protagonist Therapeutics (PTGX)

H.C. Wainwright analyst Douglas Tsao reiterated a Buy rating on Protagonist Therapeutics today and set a price target of $117.00.

### Claim 55% Off TipRanks

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks

Tsao covers the Healthcare sector, focusing on stocks such as Pacira Pharmaceuticals, Rezolute, and Xenon. According to TipRanks, Tsao has an average return of 21.2% and a 52.10% success rate on recommended stocks.

In addition to H.C. Wainwright, Protagonist Therapeutics also received a Buy from Barclays’s Etzer Darout in a report issued today. However, on the same day, Goldman Sachs maintained a Hold rating on Protagonist Therapeutics (NASDAQ: PTGX).

### Related Stocks

- [PTGX.US](https://longbridge.com/en/quote/PTGX.US.md)
- [LABU.US](https://longbridge.com/en/quote/LABU.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [BIB.US](https://longbridge.com/en/quote/BIB.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [IHE.US](https://longbridge.com/en/quote/IHE.US.md)
- [IXJ.US](https://longbridge.com/en/quote/IXJ.US.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)
- [ARKG.US](https://longbridge.com/en/quote/ARKG.US.md)
- [VHT.US](https://longbridge.com/en/quote/VHT.US.md)
- [XLV.US](https://longbridge.com/en/quote/XLV.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md)
- [PCRX.US](https://longbridge.com/en/quote/PCRX.US.md)
- [RZLT.US](https://longbridge.com/en/quote/RZLT.US.md)
- [XENE.US](https://longbridge.com/en/quote/XENE.US.md)
- [BARC.UK](https://longbridge.com/en/quote/BARC.UK.md)
- [BCS.US](https://longbridge.com/en/quote/BCS.US.md)
- [GS.US](https://longbridge.com/en/quote/GS.US.md)
- [W4VR.SG](https://longbridge.com/en/quote/W4VR.SG.md)

## Related News & Research

- [LifeSci Capital Sticks to Their Buy Rating for Tenax Therapeutics (TENX)](https://longbridge.com/en/news/286648286.md)
- [Roth MKM Sticks to Their Buy Rating for Capricor Therapeutics (CAPR)](https://longbridge.com/en/news/286497683.md)
- [Acrivon Therapeutics, Inc. (ACRV) Receives a Buy from Oppenheimer](https://longbridge.com/en/news/286428001.md)
- [Zentalis to Present Phase 1b MUIR Data: 39% ORR, 7.3‑month PFS; 50% ORR at 250 mg Cohort](https://longbridge.com/en/news/287276070.md)
- [Relay drug shows early promise against rare blood vessel diseases](https://longbridge.com/en/news/287094432.md)